WHO – Page 19 – Pharma.Tips

Stability data gaps during variation management – preventing PQ suspension

Addressing Stability Data Gaps During Variation Management to Prevent PQ Suspension One common but critical issue faced by pharmaceutical manufacturers during variation management is the identification and resolution of stability…

Deviation history questioned during requalification – preventing PQ suspension

Addressing Deviation History During Requalification to Prevent PQ Suspension In the dynamic environment of pharmaceutical manufacturing, the questioning of deviation history during requalification for WHO Prequalification (PQ) can present significant…

Manufacturing site not PQ-ready during WHO PQ assessment – CAPA expectations for PQ approval

Ensuring Your Manufacturing Site is PQ-Ready for WHO Assessments: A Comprehensive Playbook Manufacturing sites face stringent requirements during WHO Prequalification (PQ) assessments, and any deviation can lead to a determination…

PQ dossier deficiency during variation management – PQ assessment risk and mitigation

Mitigating Deficiencies in PQ Dossier During Variation Management Managing variations within the pharmaceutical manufacturing space is fraught with challenges, particularly when it comes to maintaining compliance with Prequalification (PQ) requirements…

API change not reported during requalification – documentation gaps reviewers flag

Addressing API Changes Not Reported During Requalification: A Practical Playbook In the pharmaceutical manufacturing landscape, the consequences of undocumented Active Pharmaceutical Ingredient (API) changes during requalification processes can be significant.…

API change not reported during dossier submission – preventing PQ suspension

Managing Unreported API Changes During Dossier Submission to Prevent PQ Suspension In the dynamic landscape of pharmaceutical manufacturing and regulatory compliance, the failure to report Active Pharmaceutical Ingredient (API) changes…

Documentation not aligned to WHO during API sourcing – CAPA aligned to WHO standards

Aligning API Sourcing Documentation with WHO Standards: A Practical Guide In the pharmaceutical industry, ensuring the alignment of documentation with WHO standards during Active Pharmaceutical Ingredient (API) sourcing is crucial…

Supplier WHO GMP non-compliance during API sourcing – WHO inspector expectations explained

Understanding WHO GMP Non-Compliance During API Sourcing: A Practical Playbook Supplier WHO GMP non-compliance during API sourcing poses significant risks to pharmaceutical manufacturers, potentially leading to serious regulatory repercussions and…

API site WHO GMP risk during prequalification preparation – evidence pack for WHO audits

Managing WHO GMP Risks During API Site Prequalification Preparation As pharmaceutical professionals navigate the regulatory landscape for prequalification, ensuring compliance with WHO GMP standards is a daunting but critical task.…

Inadequate WHO GMP training during remediation planning – gap remediation roadmap

Comprehensive Guide for Addressing Inadequate WHO GMP Training in Remediation Planning In the fast-paced world of pharmaceutical manufacturing, inadequate WHO GMP training during remediation planning can significantly hinder compliance efforts.…

Inconsistent alignment with WHO TRS during API sourcing – gap remediation roadmap

Strategies for Bridging Gaps in API Sourcing Alignment with WHO TRS Inconsistent alignment with WHO TRS during API sourcing can lead to quality discrepancies, regulatory failures, and potential disruptions in…

WHO GMP gap identified during WHO inspection – evidence pack for WHO audits

“`html Addressing WHO GMP Gaps Identified in Inspections: An Actionable Playbook In the dynamic landscape of pharmaceutical manufacturing, identifying and addressing gaps in Good Manufacturing Practice (GMP) compliance is crucial…